Today: 12 November 2025
Subscribe
Browse Tag

Acquisition

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure. Key takeaways (Nov. 10) What changed today The revised terms, line by line (from today’s 8‑K) Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement: Why Novo bowed out — and the FTC’s
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and extends its cash runway into 2029. The announcement sent GLTO screaming higher in pre‑market trading. GlobeNewswire Key takeaways Why this matters for patients and investors Damora’s approach is aimed squarely at mutant calreticulin (mutCALR)—a well‑validated genetic driver in segments of essential thrombocythemia (ET) and myelofibrosis (MF). Targeting this neoantigen has attracted growing interest as researchers seek more disease‑modifying options beyond
10 November 2025
 ·  ·  ·  ·  · 
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next. Updated: November 8, 2025 Top takeaways What changed on Nov. 7–8 Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of $65.60 per share in cash and a contingent value right of up to $20.65). The board unanimously reaffirmed its support for Pfizer’s deal, citing both superior certainty of closing and “unacceptably high legal and regulatory risk” tied to Novo’s competing
8 November 2025
 ·  ·  ·  · 
Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025

Brighthouse Financial, Inc. (NASDAQ: BHF) said this morning it has entered into a definitive agreement to be acquired by Aquarian Capital in an all‑cash deal valuing the company at approximately $4.1 billion, or $70.00 per share. The transaction would take the U.S. life insurer and annuity provider private and is expected to close in 2026, pending shareholder and regulatory approvals. Business Wire Key takeaways Deal details and timeline Under the definitive merger agreement, Aquarian will acquire all outstanding BHF common shares for $70 in cash. Preferred stock will remain outstanding with the same terms and dividends, and outstanding junior subordinated
6 November 2025
 ·  ·  ·  ·  · 
Marvell Technology Soars After Report SoftBank Explored Takeover, Eyeing ARM Tie‑Up — Nov. 6, 2025

Marvell Technology Soars After Report SoftBank Explored Takeover, Eyeing ARM Tie‑Up — Nov. 6, 2025

Marvell Technology (NASDAQ: MRVL) jumped on Thursday after Bloomberg reported that SoftBank Group explored a takeover of the U.S. chipmaker earlier this year—an approach that, if completed, would have marked the largest deal in semiconductor history. While no agreement was reached and talks aren’t active, people familiar with the matter said interest could be revived. Bloomberg Why SoftBank might want Marvell SoftBank founder Masayoshi Son has been vocal about betting big on AI hardware. Marvell’s expertise in custom accelerators, high‑speed networking, and cloud/datacenter silicon could complement ARM’s CPU IP—potentially creating a portfolio spanning compute and connectivity for hyperscalers building AI
6 November 2025
 ·  ·  ·  · 
Is Warner Bros. Discovery (WBD) the Next Big Media Stock? 75% YTD Surge Sparks Buzz

Warner Bros. Discovery Stock Soars on Sale Buzz – Is a Blockbuster Media Deal Brewing?

WBD Stock Surges on Takeover Rumors Warner Bros. Discovery corporate logo signage. The media giant’s stock surged on October 21, 2025 amid speculation of a potential sale. Warner Bros. Discovery’s stock spiked sharply on October 21, 2025 after the media conglomerate signaled it might be open to a sale. In a morning announcement, WBD said its board has launched a “comprehensive review of strategic alternatives” following unsolicited takeover interest from multiple parties ts2.tech. This stunning development – just months after WBD announced plans to split into two companies – sent WBD shares up about 7–9% to nearly $20, from a
21 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties novonordisk.com. Reuters reported Novo would pay “up to $2.1 billion” for the experimental drug reuters.com. The deal is structured as a licensing asset purchase, not a full acquisition, and is expected to close in Q4 2025 marketscreener.com novonordisk.com. Novo’s Chief Scientific
15 October 2025
 ·  ·  ·  ·  ·  ·  · 
PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

PMGC Holdings (ELAB) Shares Skyrocket 230% Amid Acquisition Spree – What’s Next?

Company Overview PMGC Holdings Inc. (NASDAQ: ELAB) is a diversified holding company that grows by acquisitions. Its profile describes it as managing a portfolio of subsidiaries through strategic deals reuters.com. Notably, one subsidiary – NorthStrive Biosciences – is a biopharma/medtech firm developing aesthetic and obesity-related treatments (e.g. an engineered probiotic “EL-22” for muscle retention) reuters.com. The other arms (PMGC Research, PMGC Capital) provide R&D and investment vehicles. However, PMGC’s recent focus is industrial: it seeks cash-flow positive U.S.-based manufacturing businesses (CNC machining, packaging, etc.) to bolt onto its platform sec.gov tipranks.com. In Jan 2025 the company sold its former skincare
14 October 2025
 ·  ·  ·  · 
White Mountains Stock Skyrockets on $1.75B Bamboo Deal and Major CEO Shake-Up

White Mountains Stock Rockets +10% on $1.75B Bamboo Deal – What Investors Need to Know

Figure: White Mountains’ share price spiked on Oct. 3, 2025 after announcing the $1.75B Bamboo sale reuters.com investing.com. Stock Surge on Oct. 3, 2025 White Mountains saw one of its biggest single-day moves in years on Oct. 3, 2025. After closing the prior day near $1,665, WTM stock jumped nearly 11% intraday reuters.com, settling around $1,841 by market close (a gain of +10.62% from the previous close). This surge was driven by the surprise announcement that morning: WTM signed an agreement to sell most of its Bamboo homeowners insurance business to private equity firm CVC reuters.com investing.com. Investors reacted strongly because Bamboo had been
3 October 2025
 ·  ·  ·  ·  · 
White Mountains Stock Skyrockets on $1.75B Bamboo Deal and Major CEO Shake-Up

White Mountains Stock Skyrockets on $1.75B Bamboo Deal and Major CEO Shake-Up

Stock Performance & Market Data Price: As of Oct 3, 2025 (morning), WTM is trading around $1,820 per share markets.financialcontent.com. It opened near $1,785 and hit intraday highs ~$1,863 markets.financialcontent.com. This is significantly above the prior close of $1,664.56 on Oct 2 markets.financialcontent.com. The stock’s 52-week range is roughly $1,648–$2,023 investing.com. Daily Move: The Oct 3 rally (up ≈9.3%) was driven by the Bamboo sale announcement. YTD: For 2025, WTM is down about 5.7% markets.financialcontent.com. Over the past week, the stock had been near its 52-week low (~$1,650) before rebounding on Oct 3. Volume: The price jump was on moderate
3 October 2025
 ·  ·  ·  ·  ·  · 
Electronic Arts (NASDAQ: EA) – $50 Billion Buyout Buzz Sends Stock Soaring (Sept 2025)

Gamers Stunned: Saudi-Backed Consortium Snaps Up EA in Record $55B Deal

Key Facts: A consortium led by Saudi Arabia’s Public Investment Fund (PIF), with private equity firm Silver Lake and Jared Kushner’s Affinity Partners, will take Electronic Arts (EA) private in an all-cash transaction valuing the company at roughly $55 billion. EA shareholders get $210 per share – about a 25% premium to the pre-announcement stock price apnews.com ir.ea.com. Including debt, it is the largest leveraged buyout of a public tech company on record (well above the prior $32B Texas utilities deal) apnews.com reuters.com. The deal was approved by EA’s board and is expected to close in Q1 FY2027, pending regulatory
29 September 2025
 ·  ·  ·  ·  ·  · 
Crane NXT Stock Soars on Currency Boom and Big Acquisition – Key Highlights and 2025 Outlook

Crane NXT Stock Soars on Currency Boom and Big Acquisition – Key Highlights and 2025 Outlook

Crane NXT (CXT) Stock Analysis and News as of September 24, 2025 Crane NXT at a Glance: An Industrial Tech Spin-Off on the Rise Crane NXT, Co. (NYSE: CXT) is a premier industrial technology company that was launched as an independent public entity in April 2023 via a spin-off from Crane Co. investors.cranenxt.com investors.cranenxt.com. Headquartered in Waltham, Massachusetts, Crane NXT now has about 5,000 employees worldwide and focuses on technologies that secure, detect, and authenticate high-value items and transactions investors.cranenxt.com. In practice, this means the company makes things like advanced counterfeit-deterrent features for currency, product authentication systems for brands, and specialized payment and vending equipment (through its Crane Payment
24 September 2025
 ·  ·  ·  · 
1 2
Go toTop